Unedited news and product information from vendors.
InforMedix's Med-eMonitor, Med-eXpert Systems Achieve 89.5% Medication Adherence in HIV Patients
Mar 26, 2008 (08:03 AM EDT)
ROCKVILLE, Md., March 26 /PRNewswire-FirstCall/ -- InforMedix Holdings, Inc. , announced that results presented by Dr. David Bangsberg, an internationally renowned expert on medical adherence, at the Third International Conference on HIV Adherence, showed that HIV+ patients using its Med-eMonitor(TM) "smart pillbox" that monitors medication and care plan adherence, achieved an average 89.5% medication adherence rate. The Med- eMonitor "smart pillbox" is linked to the Med-eXpert(TM) software system that analyzes patient information and provides Web-enabled reports and urgent outbound alerts to caregivers when patients miss medication or suffer declining health.
Approximately 1.2 million people in the US are living with HIV, with an additional 40,000 becoming infected each year, costing the US health care system approximately $50,000-$75,000 per year per patient, or $50 to $75 billion in total annual costs. Average adherence to HIV antiretroviral therapy is under 70%, and 20-33% of HIV-positive patients will miss at least one of their doses over any given 3-day period. Given that a 10% difference in adherence by individuals is associated with a doubling of viral load, and a 21% increase in the risk of progression to full-blown AIDS; based upon the statistics above Med-eMonitor/Med-eXpert offers the potential for a 40% decrease in the risk of an HIV patient developing full blown AIDS.
The challenging population of 76 patients that were enrolled in the program not only suffered from HIV infection, but frequently were also suffering from drug abuse and severe mental illness, and were near-homeless.
According to Dr. Bangsberg "Without near-perfect adherence, complex anti- retroviral cocktails simply do not work, yet trying to improve adherence to HIV therapy today is like trying to monitor thousands of patients with high blood pressure - but with no equipment."
Dr. Bangsberg went on to say, "We were pleased with how well the Med- eMonitor System functioned in this very challenging population. The InforMedix field support team was also exemplary in their assistance, with rapid response to our needs."
Dr. Bangsberg is an associate professor of medicine in residence in the Division of Infectious Diseases and the San Francisco General AIDS Division at UCSF. He directs the Epidemiology and Preventions Interventions Center. Dr. Bangsberg's research program focuses on treatment outcomes in impoverished populations domestically and internationally. The REACH cohort of HIV positive homeless and marginally housed individuals forms the basis of his domestic research program, and the Uganda Antiretroviral Treatment Outcomes (UARTO) cohort of individuals on generic therapy in Uganda forms the basis of his international research.
According to Bruce A. Kehr, M.D., chairman and Chief Executive Officer of InforMedix, "We are extremely pleased with the outcome in this highly challenging population, which continues to document medication adherence rates averaging 90% or greater through the use of our Med-eXpert System. This rate of adherence has also been clinically proven in patients with diabetes, congestive heart failure, schizophrenia and those needing stroke prevention therapies. Med-eXpert's proprietary algorithms for data analytics, trend analysis, reporting, and automated caregiver alerts; combined with its Web- enabled programming of our Med-eMonitor and Med-ePhone(TM) portable patient appliances, have once again proven their effectiveness."
InforMedix, Inc., based in Rockville, Maryland, has developed the Med- eMonitor(TM) System as The Medication Adherence Solution for consumer product and disease management markets, to deliver peace-of-mind, improved independent living, and better health outcomes to patients and their loved ones. The Med- eMonitor System ("Medication, Safe and Easy"(TM)) integrates a portable patient-interactive "smart pillbox", hardware, software, and 24/7 monitoring. This is designed to enable chronically ill patients and their loved ones, professionals in disease management programs, and medical researchers to efficiently monitor and manage Med-eMonitor users' medication and care plan adherence, clinical response, and drug safety. For more information, visit http://www.informedix.com .
Safe Harbor Statement
This press release may contain forward looking statements that involve risks and uncertainties, including statements regarding our business strategy and development plans, plans for entering into new businesses, anticipated sources and uses of funds and other statements regarding our plans, objectives, expectations and intentions that are not historical facts. Because these forward-looking statements involve risks and uncertainties, actual results could differ materially from those discussed in this press release. These risks and uncertainties are described in greater detail in the reports that we file with the Securities and Exchange Commission. Our actual results, performance or achievements may vary materially from those expressed or implied in any forward-looking statements. All forward-looking statements reflect our beliefs and expectations as of the date of this press release and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise.
CONTACT: Kate Kimmins of InforMedix, +1-301-984-1566, email@example.com, or Tom Dean of Murdock Capital Partners,+1-212-421-2545,
Web site: http://www.informedix.com/